Why We Invested in Flomics: Pioneering the Future of Cancer Detection

In our continuous quest to back groundbreaking innovations, we are proud to introduce Flomics, the newest addition to the Decelera portfolio, from our 2022 program. They were one of the top 20 startups in our Decelera Menorca Program from over 1100 contenders. Flomics is pioneering early cancer detection through next-generation sequencing, aiming to transform healthcare with its cutting-edge technology. The vision of Flomics aligns with the ethos of Decelera, which fosters not just the growth of startups but also the enhancement of creativity, culture, and decision-making acumen. Flomics is not just a company; it’s a promise of early cancer detection that could revolutionize healthcare. Here’s what sets Flomics apart:

After the Holy Grail:

The liquid biopsy market is ripe for innovation, and Flomics is emerging as a significant player with its multi-cancer blood test. This technology is poised to transform the cancer diagnosis landscape, offering early detection through RNA biomarkers, crucial in improving patient outcomes and reducing healthcare costs in a $185bn market.

Expert Validation

Garnering industry recognition, Flomics was handpicked for Illumina Inc.’s prestigious 2020 accelerator program. Post-attendance at Decelera 2022, the company underwent extensive technical due diligence. The results? A breakthrough technology with excellent sensitivity and specificity, validated further by the investment from Pangaea Oncology.

Strong team and support:

Flomics isn’t just about innovation; it’s about people. The team’s diverse expertise won positive feedback during due diligence. Coupled with active engagement from Decelera’s advisors, Flomics is equipped with the right mix of passion and expertise to thrive.

Financial Overview:

Even in the R&D phase, Flomics has begun to turn heads with its revenue-generating consulting services. This early financial indicator underscores their capability to monetize their expertise and promises a sustainable and prosperous future.

Championing Health: A Commitment Beyond Profit

At the heart of our decision to invest in Flomics lies a profound commitment to people’s health. Early cancer detection is more than an advancement in medical technology — it’s a lifeline. Flomics’ breakthroughs in RNA biomarker research could lead to earlier and more accurate diagnoses, dramatically increasing survival rates and transforming patient experiences. By prioritizing patient health and well-being, our investment in Flomics transcends financial interests, embodying our dedication to societal impact and the betterment of global healthcare outcomes. This is an investment in the well-being of individuals worldwide, an effort to turn the tide against one of humanity’s most formidable adversaries.

Investing in Flomics is not just investing in a company; it’s investing in the potential to save lives through early cancer detection. It’s a leap into a future where cancer can be confronted before it’s too late, and we at Decelera are thrilled to be a part of this journey.